Active substanceSodium hydroxybutyrateSodium hydroxybutyrate
Similar drugsTo uncover
  • Sodium oxybate
    solution w / m in / in 
  • Dosage form: & nbspsolution for intravenous and intramuscular administration
    Composition:

    1 ml of the solution contains:

    Active substance:

    sodium oxybutyrate - 200 mg.

    Excipients:

    Hydrochloric acid (hydrochloric acid) or sodium hydroxide - up to pH 7.7 - 9.0, water for injection - up to 1 ml.

    Description:

    Transparent colorless or slightly yellowish liquid with a specific odor.

    Pharmacotherapeutic group:Means for non-induction general anesthesia
    ATX: & nbsp

    N.01.A.X   Other drugs for general anesthesia

    Pharmacodynamics:

    Sodium oxybutyrate refers to the means for long-acting narcosis. It is a synthetic analogue of a natural metabolite found in the central nervous system. Has sedative, hypnotic, anesthetic and antihypoxic effect. In small doses, the drug exhibits a tranquilizing effect, prevents neurotic disorders and vegetative reactions to stressful effects. In large doses causes a state of anesthesia and muscle relaxation. Sodium hydroxybutyrate does not inhibit the cardiovascular system, increases the contractility of the myocardium and improves microcirculation,increases glomerular filtration (stabilizes kidney function in conditions of blood loss), has anticonvulsant activity, increases the body's resistance to the effects of various types of oxygen deficiency.

    Pharmacokinetics:Easily penetrates through gistogematicheskie barriers, incl. blood-brain barrier. When administered intravenously, up to 70% of the drug is excreted from the blood for 2-3 hours.
    Indications:

    - Non-anional anesthesia in non-cavitary minor traumatic operations;

    - for the anesthetization of labor (especially pathological);

    - as an antishock agent for the purpose of sedative and hypnotic action.

    - introductory and basic anesthesia;

    - heart surgery.

    Contraindications:

    Hypokalemia, severe toxicosis of pregnancy with hypertension, myasthenia gravis.

    Dosing and Administration:

    Intravenously in a dose: 50-70 mg / kg to the weakened patient, physically strong - 70-120 mg / kg, at a speed of 1-2 ml / min, dissolved in 50-100 ml of 5-40% glucose solution. The duration of the infusion is 10-20 minutes. This method of administration of an anesthesiologist can be used in cases where the drug is administered to a patient in the ward. After 5-7 minutes from the beginning of the drug, the patient falls asleep.It can also be administered for 1-2 minutes at a rate of 35-40 mg / kg in the maintenance mixture Sodium narcosis oxybugarate is additionally administered at a rate of 40 mg / kg. Anesthesia of sufficient depth for surgical intervention comes in 30-40 minutes from the beginning of the injection. This technique allows you to quickly (after the introduction of muscle relaxants) to intubate the trachea and begin surgical intervention with the additional administration of painkillers.

    For introductory anesthesia in children sodium oxybutyrate prescribe intravenously drip in a dose of 100 mg / kg in 30-50 ml of 5% glucose solution for 5-10 minutes. Sleep occurs in 10-20 minutes. Duration of sleep from 1,5dos.

    In heart surgery sodium oxybutyrate as an antihypoxic agent and a drug that prevents unwanted reactions to cooling is used at a dose of 100 mg / kg intravenously.

    In hypoxic conditions, shock is used in a dose of 50-100 mg / kg. The maximum antihypoxic effect occurs 30-40 minutes after administration. The appearance on the electroencephalogram of slow delta waves interrupted by periods of isoelectric "silence" of the cortex is a criterion of sufficient, but not too deep (as opposed to other narcotic drugs) anesthesia.

    With prolonged administration of the drug in large doses, potassium chloride should be administered to prevent possible hypokalemia (at a dose of 1/5 of the sodium oxybushrach dose).

    For medical obstetric anesthesia, the drug is administered intravenously, slowly at a dose of 50-60 mg / kg in 20 ml of 40% glucose solution for 10-15 minutes. Sleep or superficial anesthesia lasts 1.5-3 hours. In case of transition to surgical delivery sodium oxybutyrate injected at a dose of 60-70 mg / kg and against this background, intubation anesthesia is performed with fractional administration of muscle relaxants.

    Side effects:

    Perhaps motor excitement, convulsive twitching of mimic muscles and limbs; violation of breathing until stopping (with rapid intravenous injection); at the exit from anesthesia, motor and speech excitation, hypokalemia (with prolonged use in large doses without the introduction of potassium ions) is possible; nausea and vomiting (when used in high doses). Individual patients experience drowsiness during the day.

    Overdose:

    Symptoms: stop breathing.

    Treatment: artificial ventilation of the lungs, maintenance of central nervous, cardiovascular and respiratory systems.

    Interaction:

    Strengthens (mutually) the action of narcotic analgesics and means for anesthesia A marked antagonism with bemegridom.

    Effect on the ability to drive transp. cf. and fur:During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:

    Solution for intravenous and intramuscular200 mg / ml in 5 ml ampoules.

    Packaging:

    5 ampoules in a contour cell box made of a polyvinylchloride film and aluminum foil.

    1 or 2 contourcell packs with instructions for use in a pack of cardboard or 20, 50 or 100 contour squares, together with an equal number of instructions for use, respectively, in a cardboard box or corrugated cardboard box (for inpatient).

    Scarifiers or knives are put into a pack or box ampoule. When packing ampoules with rings or break points, scarifiers or ampoule knives do not.

    Storage conditions:

    In accordance with the rules for the storage of psychotropic substances listed in List III of the List of Narcotic Drugs,psychotropic substances and their precursors subject to control in the Russian Federation ".

    In the dark place at a temperature of no higher than 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    4 years. Do not use after the expiry date printed on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-003201/07
    Date of registration:15.10.2007 / 02.02.2018
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia
    Manufacturer: & nbsp
    Information update date: & nbsp26.05.2018
    Illustrated instructions
      Instructions
      Up